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Abstract  
Inflammatory cells were obtained from the spinal cords of rats with acute experimental autoimmune 
encephalomyelitis EAE induced by inoculation with myelin basic protein MBP and adjuvants. Reverse 
transcriptase-polymerase chain reaction RT-PCR was used to investigate the expression of mRNA for 
interleukin-2 IL-2 , IL-4, IL-10 and interferon-γ (IFN-γ)  by cells from groups of rats studied 10–21 days 
after inoculation. On all days of study, the inflammatory cells, which were predominantly lymphocytes, 
expressed mRNA for IL-2, IL-4, IL-10 and IFN-γ. In the mRNA from normal rat spinal cord tissue, there 
was little expression of cytokine mRNA. Cells from a short-term MBP-reactive T cell line expressed all the 
cytokines. Densitometry was used to measure the products of PCR, to assess the expression of each 
cytokine relative to that of β-actin. IL-2 mRNA was expressed throughout the course of disease and 
reached a peak on day 18, during late clinical recovery. IFN-γ was expressed throughout the course of the 
disease and was also high during late recovery. IL-4 mRNA was present in the spinal cord throughout the 
course of the disease, with a slight rise during late recovery. Relative expression of IL-10 rose to a peak on 
days 17–19, during late recovery from clinical disease. This study indicates that IL-2, IL-4, IL-10 and IFN-
γ are expressed by inflammatory cells in the spinal cord in EAE, with the relative expression of all 
cytokines being high during late clinical recovery.  
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1. Introduction 
Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating disease of 
the nervous system. It can be induced by inoculation with myelin proteins, such as myelin basic 
protein (MBP), and adjuvants and can be passively transferred to naive animals by CD4+ T cells 
(Pettinelli and McFarlin, 1981). EAE is characterized by infiltration of the nervous system with 
activated T lymphocytes and macrophages (Raine, 1984; McCombe et al., 1992). Cloned 
encephalitogenic T cells secrete interleukin-2 (IL-2) and interferon-  (IFN- ) (Ando et al., 1989; 
Baron et al., 1993). Thus, encephalitogenic cells are Th1-like cells, as defined by the original 
concept of Mosmann and Coffman (1989) that CD4+ T cells produce either IL-2 and IFN-  (Th1 
cells) or IL-4, IL-5 and IL-10 (Th2 cells). Lewis rats spontaneously recover from acute EAE, with 
resolution of inflammation and remyelination of nerve fibres (Pender, 1989). During recovery 
from acute EAE, T cells and macrophages undergo apoptosis in the central nervous system (CNS) 
(Pender et al., 1992; Schmied et al., 1993; Nguyen et al., 1994; Tabi et al., 1994 and Tabi et al., 
1995; McCombe et al., 1996a). While apoptosis of T cells in the CNS appears to play a major 
role in the resolution of inflammation in EAE, down-regulatory T cells and anti-inflammatory 
cytokines may also be involved. Down-regulatory CD4+ T suppressor cells have been described 
in rats that have recovered from EAE(Karpus et al., 1992; Varriale et al., 1994) and rats that have 
been tolerized with low doses of encephalitogenic antigen (Chen et al., 1994). Such regulatory T 
cells secrete anti-inflammatory cytokines such as IL-4, IL-10 and transforming growth factor-  
(TGF- ) (Karpus et al., 1992; Chen et al., 1994). There is evidence that, during spontaneous 
recovery from EAE, anti-inflammatory cytokines such as IL-10 (Kennedy et al., 1992; Issazadeh 
et al., 1995a) are present in the CNS. IL-4 has also been found in the spinal cords of mice with 
EAE (Kennedy et al., 1992). The role of IFN-  in EAE requires clarification because, although 
IFN-  has been implicated in the pathogenesis of EAE, there is also evidence that it may play a 
protective role in EAE (Billiau et al., 1988; Voorthuis et al., 1990). We performed the present 
study to determine whether clinical recovery from EAE is associated with a selective increase in 
the expression of anti-inflammatory (Th2) cytokines, compared to that of pro-inflammatory (Th1) 
cytokines. We used semi-quantitative reverse transcriptase-PCR (RT-PCR) to assess the 
expression of IL-2, IL-4, IL-10 and IFN-  by inflammatory cells extracted from the spinal cord 
of rats with acute MBP-EAE, from days 10–21 after inoculation.  
2. Materials and methods 
2.1. Induction of EAE 
EAE was induced in male Lewis rats (JC strain), aged 8–10 weeks, obtained from the Central 
Animal Breeding House of the University of Queensland. MBP was prepared from guinea pig 
brains by the method ofDeibler et al. (1972). MBP in 0.9% saline was emulsified in an equal 
volume of incomplete Freund's adjuvant containing 4 mg/ml Mycobacterium butyricum. On day 
0, anaesthetized rats were inoculated in 1 hind footpad with 0.1 ml emulsion. The total dose of 
MBP was 50 g per rat. Rats were weighed on day 0 and daily from day 8. We assessed 
weakness of the tail, hindlimb and forelimb. The degree of weakness of each region was 
separately graded on a scale of 0 (no weakness) to 4 (total paralysis), as previously described 
(Pender, 1986). The scores from each region were added together to give a total clinical score 
(maximum total clinical score=12). For each experiment, we used the pooled spinal cords of 
groups of 4–6 rats that had been inoculated at the same time, and which were then sacrificed on 
the same day. Several groups of rats were used for each time-point, to provide replicates.  
2.2. Extraction of cells from spinal cord 
The cells were isolated from the spinal cords of anaesthetized rats perfused with ice-cold saline, 
as previously described (McCombe et al., 1996b). The spinal cord was removed by insufflation, 
weighed, and a single cell suspension in ice-cold RPMI 1640 containing 1% fetal calf serum 
(FCS) was prepared by passage through a 200 size mesh stainless steel sieve. The cell suspension 
was mixed with isotonic Percoll (Percoll:Hank's balanced salt solution 9:1) in a 3:2 ratio (density 
1.052) in 50 ml centrifuge tubes and centrifuged for 25 min at 640×g at 4°C. The myelin layer 
and supernatant were discarded, while the last 9 ml supernatant and the cell pellet were retained, 
resuspended, transferred to a conical 10 ml centrifuge tube, underlaid with 1 ml Ficoll and 
centrifuged for 20 min at 600×g at 4°C. Cells were harvested from the interface above the Ficoll, 
resuspended in medium, washed once and counted. For flow cytometry and RNA extraction, the 
cells were then passed through a nylon wool column, using our previously described methods 
(Tabi et al., 1994). The number of cells remaining after passage through the nylon wool was 
counted, and the yield of cells after passage through the nylon wool was calculated.  
2.3. Labelling of cells and flow cytometric analysis 
The cells were labelled for flow cytometric analysis using our previously described methods 
(McCombe et al., 1996b). Aliquots of 105–106 cells were washed with a 1:1 solution of serum in 
phosphate-buffered saline (PBS) containing 1% fetal calf serum and 0.1% sodium azide, then 
incubated with primary antibodies in PBS/azide for 30 min at 4°C. Samples were washed and 
incubated with a secondary antibody for 30 min at 4°C in the dark. Cells were washed twice with 
PBS, then resuspended in 1 ml of ice-cold 50% ethanol and fixed overnight at 4°C. Samples were 
kept on ice, in the dark, and analyzed using a Becton Dickinson FACScan. Flow cytometric data 
were analyzed using Lysis II Software (Becton Dickinson). Background fluorescence, obtained 
by labelling the cells with isotype-control antibodies and FITC-conjugated secondary antibody, 
was subtracted from the test values. We used the following primary antibodies: OX19 (Dallman 
et al., 1984), which labels CD5; R73 (Hünig et al., 1989), which labels the T cell receptor 
(TCR ); R78 (Torres Nagel et al., 1993), which labels V 8.2+ T cells which are the 
predominant encephalitogenic cells in MBP-EAE (Imrich et al., 1995); OX1 (Sunderland et al., 
1979), which labels the leukocyte common antigen (CD45) which is expressed in high levels on 
cells of haematogenous origin and in lower levels on microglia (Sedgwick et al., 1991). The 
secondary antibody was fluorescein isothiocyanate (FITC)-conjugated F(ab′)2 rabbit anti-mouse 
IgG (STAR 41) (Serotec).  
2.4. mRNA extraction and reverse tanscriptase-PCR (RT-PCR) 
Messenger RNA was extracted from spinal cord inflammatory cells using Pharmacia QuickPrep 
Micro mRNA Purification Kit (a guanidinium thiocyanate-based extraction followed by oligo 
(dT) purification of mRNA). The yield of mRNA was 0.05–0.46 g mRNA/105 cells. The yield 
was low when the number of cells was high, indicating that we had exceeded the capacity of the 
extraction kit. The mRNA was stored at −20°C before RT-PCR. For most samples, the mRNA 
was subdivided and the entire RT-PCR process was performed in duplicate or triplicate. Samples 
of mRNA (0.05 g) were reverse transcribed using random hexamers as primers and MuLV 
reverse transcriptase under the following conditions: 5 mM MgCl2, 50 mM KCl, 10 mM Tris–
HCl (pH 8.3), 1 mM dNTPs, 5 M Random Hexamers (Gibco BRL), 1 U/ l RNase Inhibitor 
(Perkin Elmer), 2.5 U MuLV reverse transcriptase (Perkin Elmer) and 0.05 g poly(A+)mRNA, 
in a total volume of 20 l. Samples were incubated at room temperature for 10 min prior to 
reverse transcription. The reactions were mineral oil-overlaid and carried out in thin-walled tubes 
in a Perkin Elmer DNA Thermal Cycler (15 min at 42°C, 5 min at 99°C and 5 min at 5°C).  
PCR was carried out under the following conditions: 3.2 mM MgCl2, 10 mM KCl, 62 mM Tris–
HCl (pH 8.3), 16 mM (NH4)2SO4, 0.008% (w/v) Tween, 0.2 mM dNTPs, 0.15 M of each primer 
and 0.02 U/ l Red Hot Taq DNA Polymerase (Integrated Sciences) in a total reaction volume of 
100 l (that contained the entire 20 l RT reaction). The reactions were mineral oil-overlaid and 
carried out in thin-walled tubes in a Perkin Elmer DNA Thermal Cycler (2 min at 95°C, then, 37 
cycles of 1 min at 95°C and 1 min at 60°C [20 cycles for -actin]; then, 7 min at 72°C). Fig. 1 
shows the relationship of cytokine product to cycle number. Primers with the following sequences 
were synthesized by the Queensland Institute of Medical Research. 
  
Fig. 1. Relationship of cytokine product intensity (measured by densitometry) to number of cycles of PCR, 
for mRNA extracted from spinal cord inflammatory cells on day 14 after inoculation. This graph is a 
composite of 3 experiments which measured the increases in product intensity from 30–35, 35–37, and 37–
42 cycles for IL-2, IL-4, IL-10, and IFN-  and from 15–20 and 20–25 for -actin. We chose to use 37 
cycles of amplification, which always gave readily visualized product from all cytokines studied. Because 
this degree of amplification is near the plateau phase of the reaction, we may have underestimated high 
levels of mRNA expression.  
The primer sequences for IL-2, IL-10 and IFN-  were those used by Weinberg et al. (1993) in a 
study of MBP-EAE in the rat. The primers for IL-4 and -actin were those used by McKnight et 
al. (1991). Except for those indicated with *, the sequences are specific for the rat sequences as 
reported for -actin (Nudel et al., 1983) (Genbank J00691), IL-2 (McKnight et al., 1989) 
(Genbank M22899), IL4 (McKnight et al., 1991) (Genbank X16058), IL-10 (Feng et al., 1993) 
(Genbank X60675) and IFN-  (Dijkema et al., 1985) (Genbank X0237, X0236, X0235). The 
sequences indicated by ‘*' are specific for mouse sequences and differ from the rat sequences by 
the number of base pairs shown in parentheses. The predicted product sizes are: -actin: 607 bp; 
IL-2: 449 bp; IL-4: 378 bp; IL-10: 201 bp; IFN- : 383 bp. The sequences chosen all crossed exon 
boundaries. RT-PCR products (15 l of product loaded per lane) were visualized under ultraviolet 
light after electrophoresis on a 2% agarose gel in TBE buffer (10 mM Tris, 90 mM Boric acid, 1 
mM EDTA) containing 0.5 g/ml ethidium bromide. Because RT-PCR was performed in 
duplicate or triplicates, 2–3 gels were obtained from each group of rats. To measure the intensity 
of product, gels were photographed using positive/negative Polaroid film, and negatives were 
analyzed to determine the intensities of cytokine bands and -actin control bands, using a 
Molecular Dynamics densitometer and ImageQuant software.  
2.5. Identification of products 
RT-PCR products were dot-blotted onto positively-charged nylon membranes (Zetaprobe 
membrane, BioRad) using a Bio-Dot Microfiltration Apparatus (BioRad) according to the 
manufacturer's instructions. Twenty microliter aliquots of diluted cDNA, at dilutions ranging 
from 1 in 5 to 1 in 100, in 10 mM Tris–HCl, 1 mM EDTA (pH 8), were denatured by the addition 
of NaOH and EDTA to a final concentration of 0.4 M NaOH, 10 mM EDTA, in a final volume of 
50 l. Samples were then heated at 100°C for 10 min, followed by rapid cooling on ice. After 
application of the samples to the membrane, 0.4 M NaOH was applied to promote binding of 
DNA to the membrane. Membranes were removed from the dot-blotting apparatus, rinsed in a 
solution of sodium chloride/sodium citrate (SSC) (0.03 M Na3Citrate, 0.3 M NaCl), and then air-
dried. If membranes were not to be used the same day, they were baked at 80°C and then stored 
between 2 sheets of filter paper in a sealed plastic bag at room temperature. To identify the RT-
PCR products bound to the membranes, we used the following probe sequences, which are 
specific for rat cytokines (Barton et al., 1995) and which were synthesized by Gibco BRL Life 
Technologies: 
 
The probes were labelled, hybridized to the membranes and detected using a chemiluminescence 
system (ECL 3′-oligolabelling and detection system, Amersham). All reagents (except standard 
buffers) were supplied with the kit, and the suggested protocol was followed. Briefly, probes 
were labelled at the 3′ hydroxyl terminal with fluorescein-11-dUTP, in a reaction catalyzed by 
terminal deoxynucleotidyl transferase. Probes were hybridized to the dot-blotted membranes 
during an overnight incubation at 42°C, at a concentration of 10 ng of probe per milliliter of 
hybridization buffer. To allow only perfectly matched sequences to remain bound, we performed 
stringency washes at 5°C below the Tm of the probe, calculated according to the following 
formula: Tm=81.5+(16.6×[moles Na+])+(0.41×[% GC bases])−(675/primer length)−(0.61×[% 
formamide]). The following conditions were used: -actin: 0.15×SSC, 0.1% sodium dodecyl 
sulphate (SDS), 42°C; IL-2: 0.4×SSC, 0.1% SDS, 42°C; IL-4: 0.1×SSC, 0.1% SDS, 47°C; IL-10: 
1×SSC, 0.1% SDS, 42°C; IFN- : 0.2×SSC, 0.1% SDS, 43°C. In a two-stage protocol, 
probe/DNA hybrids were detected. The membranes were incubated with horseradish peroxidase-
conjugated antibody to fluorescein, followed by incubation with the supplied Detection Reagents. 
Light emission due to the enzymatic reduction of peroxide, coupled with luminol oxidation and 
subsequent breakdown was detected with blue light-sensitive film (Kodak Biomax XL).  
2.6. Presentation of results 
The results are mainly presented as the intensities of amplification product for each cytokine 
relative to that for -actin. Such a comparison of results from different days and different 
samples assumes that -actin expression is constant and that, as has recently been shown by 
Bishop et al. (1997), the RT-PCR reaction is reproducible. When possible, the RT-PCR reaction 
was performed in duplicate or triplicate for each sample of mRNA. The correlation co-efficient 
(r) between paired samples was 0.70. Because the RT-PCR reaction may become nonlinear at the 
extremes of the range, the numerical values obtained for these ratios may not reflect the number 
of molecules of product. Because the number of cycles used (37) was near the plateau phase of 
the PCR reaction, we may have underestimated higher levels of mRNA expression. However, 
because the reactions were performed under the same conditions on all the days of study, a 
comparison of the relative expression of each cytokine can be made, with higher values indicating 
greater expression of cytokine. The results are also presented as cytokine mRNA expression per 
gram of spinal cord. This was calculated as cytokine expression relative to -actin (an index of 
cytokine expression per cell, assuming that all cells have the same content of -actin mRNA) 
multiplied by the yield of cells per gram of spinal cord. Data was analyzed with Kruskal–Wallis 
one-way analysis of variance (ANOVA) for ranks with Dunn's post-test comparing all other days 
with day 18, using Sigmastat Version 2 (Jandel Scientific software).  
3. Results 
3.1. Details of rats used for RT-PCR study 
Table 1 shows the details of the rats used for the RT-PCR study. On each day of study, 3–5 
groups of rats, each group comprising 4–6 rats, were used. For each group of rats, the spinal cords 
were combined before the extraction of cells. For controls, we studied total mRNA extracted from 
the spinal cord tissue of normal rats and mRNA obtained from a short-term MBP-reactive Lewis 
rat T cell line (kindly supplied by Ms. Jackie Harness).  
 3.2. Analysis of the cells obtained from the spinal cord 
Table 1 shows the number of cells and the percentage of the original cells that remained after 
passage through nylon wool. Before nylon wool extraction, many macrophages could be seen by 
microscopy in the cell extract, whereas after nylon wool extraction, the number of macrophages 
visible by microscopy was reduced. The yield of cells after nylon wool extraction was lower on 
the later than on the earlier days of study, suggesting that the cells obtained in the later stages of 
the disease contained a higher proportion of macrophages. To compare the cell populations on 
different days after inoculation, we used flow cytometry analysis of another series of rats. Table 2 
shows the percentage of cells (after passage through nylon wool) that were stained with 
antibodies to CD45, CD5, TCR  and V 8.2. On days 12–21, the percentage of cells that were 
CD45+ (cells of haematogenous origin) was around 90%. The CD45+ cell population contained 
CD45high cells (including lymphocytes and macrophages) and CD45low cells which appear to be 
microglia (Sedgwick et al., 1991; McCombe et al., 1994). The percentages that were CD5+ and 
TCR + remained constant from days 12–19, but declined on day 21, after recovery from the 
disease. The CD5− cells are, in part, accounted for by CD45low cells (microglia). The remaining 
CD5− cells are likely to be macrophages.  
 
3.3. Results of RT-PCR 
In rats with EAE, we found intense product bands for IL-2, IL-10 and IFN-  on all days after 
inoculation. The band for IL-4 product was less intense. For a control, we studied mRNA 
extracted from spinal cord tissue of a normal rat. From this mRNA, we found only faint product 
bands for IL-2, IL-4 and IFN-  and there was no IL-10 product. Products for all cytokines were 
amplified from mRNA from the MBP-reactive T cell line. The cytokine products were of 
predicted size. Dot-blotting with labelled probes confirmed the identities of the cytokine products. 
In all cases, the PCR product gave a positive result with the specific probe and a negative result 
with the irrelevant probes. Fig. 2 shows the expression of IL-2, IL-10, IL-4 and IFN- , measured 
by densitometry, and normalized against expression of -actin. The mean density of -actin 
product varied from 41–91 units. The level of expression of mRNA for IL-2, relative to that for 
-actin, reached a peak on days 18–19 during late clinical recovery. IFN-  expression reached a 
peak on days 17–19. Relative expression of IL-4 did not vary greatly through the course of the 
disease but was highest on days 17–19. Relative expression of IL-10 rose from day 10 to reach a 
peak on days 17–19, during late clinical recovery. The observed increase in the relative 
expression of cytokines on days 17–19 could indicate either that individual cells from which the 
mRNA was extracted were producing relatively more cytokine mRNA, or that the proportion of 
cells producing cytokine mRNA was greater. Table 3 shows the expression of cytokine mRNA 
per gram of spinal cord. It can be seen that cytokine mRNA production per gram of spinal cord 
reached a peak on days 13–14 at the time of peak clinical disease.  
 Fig. 2. Mean (±SE) of the ratios of cytokine expression to -actin expression from controls (NSC: normal 
spinal cord; Line: an MBP-reactive T cell line) and spinal cord inflammatory cells from rats with EAE on 
days 10–21 after inoculation. For cytokine mRNA, 37 PCR cycles were performed and for -actin, 20 
cycles were performed. The intensity of the product was measured by densitometry. With Kruskal–Wallis 
ANOVA for ranks, p<0.05 for each cytokine. The asterisks indicate values that were significantly different 
(p<0.05) from the value for day 18.  
 4. Discussion 
We studied the expression of cytokine mRNA by inflammatory cells obtained from the spinal 
cords of Lewis rats with actively induced acute MBP-EAE. Cytokine mRNA expression does not 
necessarily reflect protein production by cells, but changes in mRNA expression through the 
course of the disease are likely to reflect modulation of the activity of cytokine-producing cells. 
Semi-quantitative RT-PCR was used to compare the results from rats studied on days 10–21 after 
inoculation. The technique we used may have underestimated higher levels of mRNA expression, 
because the number of cycles used was near the plateau phase. We have presented the results as 
cytokine mRNA expression relative to that of -actin (Fig. 2). This gives an index of cytokine 
production per cell, and will increase if a higher proportion of the cells in the population express 
cytokine mRNA or if individual cells produce more cytokine mRNA. These results may be 
compared with those of Tanuma et al. (1997), who used competitive PCR in a study of cells 
extracted from the spinal cord of Lewis rats with EAE. We have also presented the results as 
cytokine mRNA expression per gram of spinal cord (Table 3), which can be compared with the 
results of Issazadeh et al. (1995a) and Issazadeh et al. (1995b), who used in situ hybridization to 
study cytokine mRNA expression per unit area of spinal cord section.  
In our study, we used passage over nylon wool to enrich our population for lymphocytes. The 
study population was predominantly (70%) CD5+, indicating that the majority of the cells were T 
lymphocytes. Therefore, this study predominantly reflects cytokine mRNA expression by T 
lymphocytes. The CD5− cells were, in part, accounted for by CD45low cells that appear to be 
microglia (Sedgwick et al., 1991). Although we did not stain with a marker for macrophages, the 
remaining CD5− cells are likely to be macrophages. Microglia and macrophages may secrete IL-
10, but do not secrete the other cytokines of interest in this study. The majority of T cells in the 
spinal cord of Lewis rats with acute MBP-EAE are CD45RClow (activated cells) (McCombe et al., 
1992). The percentage of these cells that are V 8.2+(the predominant encephalitogenic cells) 
declines during clinical recovery from the disease (McCombe et al., 1996a). We found that IL-2, 
IL-4, IL-10 and IFN-  were expressed by inflammatory cells from the spinal cords of rats with 
MBP-EAE. In contrast, there was minimal expression of IL-2, IL-4 and IFN-  and no expression 
of IL-10 in normal spinal cord. Messenger RNA from a short-term MBP-reactive T-cell line 
expressed all the cytokines studied. Thus, our study found that Th1 (IL-2 and IFN- ) and Th2 
(IL-4 and IL-10) cytokines are expressed by inflammatory cells in the CNS throughout the course 
of the disease.  
Semi-quantitative studies were performed to examine the expression of cytokine mRNA from day 
10 (early in the disease) until day 21 (when the majority of rats have completely recovered). 
Expression of IL-2 mRNA (relative to -actin) reached a peak on day 18 during late clinical 
recovery. The peak of IL-2 production per gram of spinal cord was on day 14, at the peak of the 
clinical disease. Our findings of IL-2 mRNA expression throughout the clinical disease are 
consistent with previous studies indicating the importance of IL-2 in EAE. IL-2 is known to be 
present in the CNS in EAE (Baker et al., 1991; Merrill et al., 1992; Renno et al., 1994) and 
encephalitogenic T cell clones secrete IL-2 (Ando et al., 1989; Baron et al., 1993). Expression of 
IFN-  (relative to -actin) was observed throughout the course of the disease, with a peak on 
days 17–19, during late clinical recovery. Our findings of IFN-  expression differ from those of 
Tanuma et al. (1997), who found peak expression on days 11 and 12, but did not study expression 
on days 17–19. We did not study day 11, and may have missed a peak at that time. Alternatively, 
our technique of semi-quantitative PCR may have underestimated such a peak. We found that the 
expression of IFN-  per gram of spinal cord reached a peak on day 14 and remained elevated 
until day 21. IFN-  has a wide range of activities and may contribute to the pathogenesis of EAE 
by the induction of major histocompatibility complex (MHC) antigen expression. IFN-  may also 
cause tissue damage by inducing NO synthase (Misko et al., 1995). The persistence of IFN-  
expression during clinical recovery could be consistent with a down-regulatory role for this 
cytokine in EAE. Such a down-regulatory role is suggested by the observations that: (1) 
administration of antibody to IFN-  can enhance EAE (Billiau et al., 1988; Voorthuis et al., 
1990), (2) intraventricular IFN-  can suppress EAE (Voorthuis et al., 1990), (3) abrogation of 
IFN-  expression makes BALB/c mice susceptible to EAE (Krakowski and Owens, 1996), and 
(4) EAE is more severe in IFN-  receptor deficient mice (Willenborg et al., 1996). IFN-  might 
down-regulate EAE through its ability to induce apoptosis of activated T cells (Liu and Janeway, 
1990). During the later stages of the disease, the pro-inflammatory functions of IFN-  may be 
blocked by TGF-  (Dore Duffy et al., 1996), thus allowing the protective role of IFN-  to 
predominate.  
Expression of IL-4 relative to -actin was observed on all days, with a rise in the levels on days 
17–19. Issazadeh et al. (1995b) found only low numbers of IL-4 mRNA-expressing cells in the 
spinal cord of rats with EAE. However, in mice, Kennedy et al. (1992) found that IL-4 was 
present in the CNS and reached a peak before the peak of the clinical disease. Our study supports 
the view that IL-4-expressing cells are present in the CNS in EAE. IL-10 expression (relative to 
-actin) increased throughout the course of the disease with maximum expression on day 18. IL-10 
was first described as a product of Th2 cells that could inhibit cytokine synthesis by Th1 cells 
(Fiorentino et al., 1989). IL-10 is now known to have a wider biological role and is an anti-
inflammatory cytokine produced by T cells, B cells and macrophages (Moore et al., 1993). These 
anti-inflammatory properties could contribute to the down-regulation of EAE. Kennedy et al. 
(1992), who studied mRNA from total spinal cord, showed that expression of IL-10 correlates 
with clinical recovery from EAE in mice. Issazadeh et al. (1995a) showed that IL-10 mRNA-
producing cells are present in the CNS of rats during and after recovery from EAE. The 
techniques used by Issazadeh et al. (1995a) detect all cytokine-producing cells, and therefore 
would detect IL-10 mRNA expression by macrophages; however, we studied a predominantly 
lymphocyte population. It is also possible that astrocytes may produce IL-10 (Mizuno et al., 
1994), but we did not find detectable IL-10 in mRNA extracted from normal spinal cord tissue. 
Our findings of IL-10 expression differ from those of Tanuma et al. (1997),who found peak 
expression on days 11 and 12. We did not study day 11, and may have missed a peak at that time. 
We found a peak of IL-10 expression (relative to -actin) on days 17–19, which were not studied 
by Tanuma et al. (1997). This peak of IL-10 expression occurred late in clinical recovery, and 
therefore is unlikely to play a primary role in the resolution of inflammation in EAE, although it 
may play a role in the subsequent regulation of inflammation. Previous studies are unclear about 
the role of IL-10 in recovery from EAE. One study in the rat (Rott et al., 1994) found that 
exogenous IL-10 reduced the severity of EAE, whereas another study, in mice, found the opposite 
(Cannella et al., 1996).  
Thus, we found increased expression of all cytokines, relative to the expression of -actin, during 
late clinical recovery, near the time that spontaneous relapses of EAE can occur. The alterations 
in cytokine expression may be due to changes in the population of cells in the spinal cord. We 
have previously shown that after the peak of clinical signs of acute MBP-EAE, there is a selective 
loss of V 8.2+ cells (the predominant encephalitogenic cells) by apoptosis in the CNS (Tabi et 
al., 1994; McCombe et al., 1996a) and suggested that this is mediated through interactions 
between Fas and Fas ligand (White et al., 1998). Fas-mediated apoptosis occurs more rapidly in 
Th1 than Th2 cells (Zhang et al., 1997), so that selective apoptosis of Th1-like encephalitogenic 
cells, with sparing of Th2 cells, could explain the observed relative increase in expression of IL-
10 in the later stages of the disease. However, this would not explain the increased expression of 
IL-2 and IFN- . The increased relative expression of cytokines during late clinical recovery could 
also reflect an influx of activated T cells from the periphery. An influx of activated T cells could 
occur after a waning in the effects of endogenous corticosteroids which have a role in clinical 
recovery from EAE (MacPhee et al., 1989) and which may act by reducing influx of cells into the 
CNS.  
In conclusion, we have found that the relative expression of the Th2 cytokine IL-10, and to a 
lesser extent the Th2 cytokine IL-4, is high in the CNS during late clinical recovery from EAE. 
However, the expression of the Th1 cytokines IFN-  and IL-2 is also high at this time. With 
further study, the original concept of clearly defined and highly polarized populations of Th1 and 
Th2 cells has been replaced by a more complex model of T cell cytokine production (Mosmann 
and Sad, 1996) in which the expression of different cytokines may be regulated independently. 
The alterations in cytokine expression in the spinal cord after the peak of the clinical disease may 
reflect the changes in the cell population in the spinal cord.  
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